Response shift - The experience of disease progression in Parkinson disease. 2017

Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
Department of Neurology, University of Maryland School of Medicine, 110 South Paca Street, 3rd Floor, Baltimore, MD 21201, United States.

To investigate response shift, the recalibration of perceived quality of life (QoL) relative to symptomatic changes in Parkinson disease (PD). Health-related QoL in PD is influenced by improvement vs. decline in disease severity. However, it is unclear how disease course changes internal standards of QoL over time. 124 PD patients were subdivided based on Total UPDRS change over 1 year (stable, improved, declined). The EuroQol Visual Analog Scale assessed QoL at baseline (T1) and 1 year later (T2). At T2, patients rated current QoL (T2-current) and reappraised their T1 QoL (T2-retrospective). Recalibration response shifts were represented by the difference between T1 and T2-retrospective QoL ratings. At follow-up (T2), the total patient sample reported no difference between current (T2 current mean (M) = 76.3) and retrospective (T2-R M = 77.8) QoL ratings. While there was no significant difference between T1 (M = 79.2) and T2-R ratings 1 year later (M = 77.8) for the total sample, there was a change by group interaction (p < 0.005) which showed that retrospectively, decliners reduced ratings (M Δ = -9.0) and improvers increased ratings (M Δ = +6.4) while stable patients did not change. When PD patients consider their health status one year ago, decliners recalibrate and downgrade last year's health assessment, while improvers upgrade last year's assessment. Changes in internal calibrations cushion periods of decline or improvement in PD such that patients tend to "stabilize" their general disease course when recalling symptom trajectory, providing insight into the process of adaptation to the effects of disease progression and treatment over time.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
June 2014, JAMA neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
August 2007, Neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
March 2007, Neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
April 2016, Neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
October 2020, Neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
October 2020, Neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
March 1999, Archives of neurology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
January 2008, Clinical neuropharmacology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
November 2018, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology,
Jessica Yang, and Brenda Hanna-Pladdy, and Ann L Gruber-Baldini, and Erik Barr, and Rainer von Coelln, and Melissa J Armstrong, and Stephen G Reich, and Lisa M Shulman
March 2018, JAMA neurology,
Copied contents to your clipboard!